Fosigotifator

Fosigotifator is an experimental small-molecule related to ISRIB licensed by Calico from University of California, San Francisco and partnered with AbbVie, which activates activator of the eukaryotic initiation factor eIF2.^[1][2][3] Abbott and Calico ran clinical trials to determine if the drug can treat amyotrophic lateral sclerosis (ALS)^[4][5][6] and major depressive disorder.^[1] A formulation of fosigotifator, as its monosodium phosphate salt mixed with tromethamine, is known as ABBV-CLS-7262. Fosigotifator has been patented by AbbVie and Calico as a prodrug for modulation of the integrated stress response pathway.^[7]

Fosigotifator

Clinical data
Other names	ABBV-CLS-7262; Fosigotifator sodium tromethamine
Legal status
Legal status	Investigational
Identifiers
IUPAC name [(2S)-1,4-Bis[[2-(4-chloro-3-fluorophenoxy)acetyl]amino]-2-bicyclo[2.2.2]octanyl]oxymethyl dihydrogen phosphate
CAS Number	2415715-84-1 2945073-88-9 (sodium tromethamine)
PubChem CID	153563259 166177193
UNII	3FQ7XKK8AY BN9FN5629V
KEGG	D13118 D13119
Chemical and physical data
Formula	C25H27Cl2F2N2O9P
Molar mass	639.37 g·mol−1

In January 2025 Abbott and Calico announced that the drug had failed a Phase 2/3 trial in ALS; in July 2025 Abbott ended its partnership with Calico.^[1]